Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 18/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16375344 | 0.89 | ALPL (0.75) | ALPLMEN1KMT2A | |
| SCHEMBL16376114 | 0.89 | ALPL (0.74) | ALPLMEN1KMT2A | |
| SCHEMBL16375017 | 0.88 | ALPL (0.78) | ALPL | |
| SCHEMBL16376116 | 0.88 | ALPL (0.76) | ALPLMEN1KMT2A | |
| SCHEMBL15212128 | 0.88 | ALPL (0.78) | ALPL | |
| SCHEMBL15212042 | 0.86 | ALPL (1.00) | ALPL | |
| SCHEMBL16376119 | 0.83 | ALPL (0.77) | ALPLMEN1KMT2A | |
| SCHEMBL16375015 | 0.81 | ALPL (0.79) | ALPLMEN1KMT2A | |
| SCHEMBL15211956 | 0.79 | ALPL (0.85) | ALPL | |
| SCHEMBL15211855 | 0.77 | ALPL (0.85) | ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458147-B2 | Sulfonamide compounds and uses as TNAP inhibitors | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150011551-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | Sanford- Burnham Medical Reseach Institute (US) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011551-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | TNNI3, TNKS1BP1, TNNT2 | ALPL 503/4885MEN1 4072/4885KMT2A 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.